Interest in Precision Medicine Grows, But Reimbursements Slow
By Andrew Joseph,
Stat News
| 12. 23. 2015
Untitled Document
Precision medicine, in which drugs are matched to individual patients, has generated tons of buzz, from patient organizations all the way to the White House. But insurers have been grappling with whether to pay for the genetic tests that often guide such treatments, and that uncertainty has had ripple effects through the biotech companies working to develop them.
The case of Foundation Medicine, based in Cambridge, Mass., demonstrates the quest companies sometimes have to undertake to get their products covered, a process complicated when that product is a cutting-edge technology insurers aren’t sure how to assess.
Foundation analyzes the genes of a patient’s tumor to identify what’s driving the cancer and, from that, to determine what treatment will work best. The company announced this week that UnitedHealth Group had started covering its genetic test for patients with a certain lung cancer. That decision, by the country’s largest private health insurer, represents a milestone for the company as it looks to strike deals with more insurers.
Read more...
Image via Flickr.
Related Articles
By Emily Mullin, Wired | 10.30.2025
In 2018, Chinese scientist He Jiankui shocked the world when he revealed that he had created the first gene-edited babies. Using Crispr, he tweaked the genes of three human embryos in an attempt to make them immune to HIV and...
Public domain portrait of James D. Watson by Cold Spring Harbor Laboratory
and the National Human Genome Research Institute on Wikimedia Commons
James Watson, a scientist famous for ground-breaking work on DNA and notorious for expressing his antediluvian opinions, died on November 6, at the age of 97. Watson’s scientific eminence was primarily based on the 1953 discovery of the helical structure of DNA, for which he, Francis Crick and Maurice Wilkins shared the 1962 Nobel Prize in Physiology or...
By Megan Molteni and Anil Oza, STAT | 10.07.2025
For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...
Paula Amato & Shoukhrat Mitalipov
[OHSU News/Christine Torres Hicks]
On September 30th, a team of 21 scientists from Oregon Health & Science University (OHSU) published a significant paper in Nature Communications, with a scientifically accurate but, to many, somewhat abstruse headline:
Induction of experimental cell division to generate cells with reduced chromosome ploidy
The lead authors were Shoukhrat Mitalipov, recently described here as “a push-the-envelope biologist,” and his long-term colleague Paula Amato. (Recall that in July the pair had co-published with...
